Table 3 Dose metrics for PTVs; median and ranges and statistical outcomes for different energies and arc arrangements for prostate and pelvic nodes (PPLN) plans

HI

1.05

1.05

1.05

1.05

1.05

1.05

(1.05–1.05)

(1.05–1.05)

(1.05–1.05)

(1.05–1.05)

(1.05–1.05)

(1.05–1.05)

CI

1.21

1.21

1.22

1.23 ^ɫ

1.23

1.22

(1.20–1.22)

(1.18–1.22)

(1.20–1.22)

(1.21–1.24)

(1.21–1.24)

(1.21–1.24)

CN

0.91

0.91

0.91

0.91

0.91

0.91

(0.89–0.92)

(0.90–0.92)

(0.91–0.92)

(0.88–0.92)

(0.89–0.92)

(0.89–0.92)

R₅₀

4.21

4.43*

4.50*

4.31

4.63*

4.64*

(4.06–4.39)

(4.31–4.60)

(4.42–4.67)

(4.17–4.43)

(4.48–4.81)

(4.57–4.79)

R₂₅

8.65

9.02*

9.19*

8.80

9.09

9.19*

(8.32–9.07)

(8.63–9.63)

(8.69–9.72)

(8.48–9.24)

(8.70–9.43)

(8.83–9.81)

67.2

D_98% (Gy)

35.7

35.8

35.9

35.7

35.8

35.8

(54.6–92.8)

(35.3–36.1)

(35.4–36.0)

(35.5–36.1)

(35.3–36.0)

(35.3–35.9)

(35.4–35.9)

D_2% (Gy)

42.0

42.0

42.0

42.0

42.0

42.1

(42.0–42.1)

(42.0–42.1)

(42.0–42.1)

(42.0–42.1)

(42.0–42.1)

(42.0–42.1)

796.2

D_98%(Gy)

24.2

24.2

24.2

24.1

24.0

24.1

(746.4 − 855.9)

(24.1–24.3)

(24.1–24.2)

(24.2–24.3)

(24.0–24.2)

(23.9–24.0)

(24.1–24.3)

D_2% (Gy)^¥

26.6

26.6

24.7

26.6

26.7

26.7

(26.6–26.7)

(26.5–26.7)

(26.5–26.7)

(26.6–26.8)

(26.6–26.8)

(26.6–26.8)